Symptoms and treatment response to florensocatib and inhaled tobramycin in bronchiectasis: Post hoc analysis of two randomized trials
Yong-Hua Gao, Xue-Shan Li, Xiao-Li Sun, Fang-Qiong Li, Lu-Yin Sun, Han-Mo Liu, Wei-Jie Guan · 2026
Read Symptoms and treatment response to florensocatib and inhaled tobramycin in bronchiectasis: Post hoc analysis of two randomized trials by Yong-Hua Gao, Xue-Shan Li, Xiao-Li Sun, Fang-Qiong Li, Lu-Yin Sun, Han-Mo Liu, Wei-Jie Guan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13589483.txt.
Description
Yong-Hua Gao and co-authors re-read two trials to ask whether symptom load foretells who gains from bronchiectasis drugs. The airway disease brings daily cough and flare-ups. Their 2026 analysis pools a pill trial and an inhaled antibiotic trial, with 224 and 357 patients. A standard symptom scale sorts patients by burden at the start. Treatment effects are then read within each burden band.
The pill cut flare-ups by over half overall, with gains in both bands but no symptom lift. The inhaled drug lifted symptom scores past the meaning threshold in high-burden patients. Its gains grew with burden. The team casts burden as a cheap sorting tool: heavy symptoms may mark who needs the germ-fighting route most.
Catalog record
| CREATOR | Yong-Hua Gao, Xue-Shan Li, Xiao-Li Sun, Fang-Qiong Li, Lu-Yin Sun, Han-Mo Liu, Wei-Jie Guan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |